Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 17 studies | 26% ± 8% | |
B cell | 14 studies | 24% ± 9% | |
CD16-positive, CD56-dim natural killer cell, human | 13 studies | 25% ± 11% | |
macrophage | 12 studies | 39% ± 19% | |
type I pneumocyte | 9 studies | 34% ± 16% | |
naive B cell | 8 studies | 19% ± 3% | |
myeloid cell | 7 studies | 32% ± 13% | |
microglial cell | 7 studies | 34% ± 12% | |
oligodendrocyte precursor cell | 6 studies | 36% ± 12% | |
monocyte | 6 studies | 34% ± 16% | |
CD16-negative, CD56-bright natural killer cell, human | 5 studies | 18% ± 3% | |
dendritic cell | 5 studies | 22% ± 4% | |
astrocyte | 5 studies | 32% ± 11% | |
club cell | 5 studies | 26% ± 8% | |
type II pneumocyte | 5 studies | 39% ± 11% | |
endothelial cell | 4 studies | 21% ± 6% | |
epithelial cell | 4 studies | 26% ± 6% | |
Mueller cell | 4 studies | 19% ± 3% | |
GABAergic neuron | 4 studies | 42% ± 15% | |
alveolar macrophage | 4 studies | 45% ± 17% | |
conventional dendritic cell | 3 studies | 20% ± 4% | |
mature NK T cell | 3 studies | 23% ± 6% | |
memory B cell | 3 studies | 20% ± 6% | |
hepatocyte | 3 studies | 34% ± 14% | |
glutamatergic neuron | 3 studies | 45% ± 3% | |
interneuron | 3 studies | 44% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 1243.42 | 89 / 89 | 99% | 13.24 | 894 / 901 |
prostate | 100% | 1646.37 | 245 / 245 | 99% | 8.41 | 497 / 502 |
lung | 100% | 3239.76 | 578 / 578 | 98% | 10.88 | 1129 / 1155 |
pancreas | 99% | 844.59 | 324 / 328 | 99% | 10.32 | 176 / 178 |
breast | 100% | 1376.11 | 459 / 459 | 98% | 8.50 | 1091 / 1118 |
esophagus | 100% | 1347.15 | 1444 / 1445 | 96% | 8.38 | 176 / 183 |
thymus | 100% | 2980.86 | 653 / 653 | 95% | 9.49 | 577 / 605 |
intestine | 100% | 1822.10 | 966 / 966 | 94% | 5.66 | 494 / 527 |
stomach | 100% | 1373.77 | 359 / 359 | 94% | 6.02 | 268 / 286 |
liver | 100% | 1612.62 | 226 / 226 | 93% | 6.46 | 379 / 406 |
bladder | 100% | 1032.48 | 21 / 21 | 93% | 6.01 | 468 / 504 |
adrenal gland | 100% | 1506.58 | 258 / 258 | 92% | 6.82 | 212 / 230 |
uterus | 98% | 918.49 | 167 / 170 | 84% | 4.85 | 384 / 459 |
ovary | 98% | 863.07 | 177 / 180 | 83% | 4.17 | 359 / 430 |
skin | 92% | 812.38 | 1660 / 1809 | 79% | 6.27 | 371 / 472 |
brain | 91% | 707.07 | 2414 / 2642 | 76% | 5.26 | 539 / 705 |
spleen | 100% | 4997.17 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.23 | 1 / 1 |
adipose | 100% | 1293.95 | 1202 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 7.32 | 43 / 45 |
blood vessel | 95% | 649.19 | 1270 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 95% | 1249.97 | 879 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 12.47 | 27 / 29 |
heart | 93% | 614.44 | 798 / 861 | 0% | 0 | 0 / 0 |
muscle | 73% | 301.52 | 589 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 26% | 1.08 | 21 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030162 | Biological process | regulation of proteolysis |
GO_1902004 | Biological process | positive regulation of amyloid-beta formation |
GO_0005802 | Cellular component | trans-Golgi network |
GO_0001540 | Molecular function | amyloid-beta binding |
GO_0005515 | Molecular function | protein binding |
Gene name | GSAP |
Protein name | Gamma-secretase activating protein (PION protein) Gamma-secretase-activating protein (GSAP) (Protein pigeon homolog) [Cleaved into: Gamma-secretase-activating protein 16 kDa C-terminal form (GSAP-16K)] Gamma-secretase activating protein |
Synonyms | PION |
Description | FUNCTION: Regulator of gamma-secretase activity, which specifically activates the production of amyloid-beta protein (amyloid-beta protein 40 and amyloid-beta protein 42), without affecting the cleavage of other gamma-secretase targets such has Notch. The gamma-secretase complex is an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein). Specifically promotes the gamma-cleavage of APP CTF-alpha (also named APP-CTF) by the gamma-secretase complex to generate amyloid-beta, while it reduces the epsilon-cleavage of APP CTF-alpha, leading to a low production of AICD. . |
Accessions | H7C0Q7 ENST00000441833.6 A4D1B5 ENST00000415112.2 ENST00000257626.12 [A4D1B5-1] B7ZL33 |